Application of triple viable bifidobacterium powder combined with triple therapy in chronic gastritis with Helicobacter pylori infection

Objective To investigate the clinical efficacy and safety of Bifidobacterium triad combined with triple therapy in the treatment of chronic gastritis with Helicobacter pylori (Hp) infection. Methods Total 178 cases of chronic gastritis with Hp infection in our hospital were selected and randomly divided into control group (89 cases, treated with triple therapy) and study group (89 cases, received additional Bifidobacterium triple viable powder). The clinical symptom score and serum gastrin level were observed, the curative effect was compared between the two groups. Results The total efficiency of the control group was 84.27% and of the study group was 95.51%, the difference was statistical significant. After the treatment, the score of stomachache and stomach bloating, dryness and bitterness of the mouth, belching and acid regurgitation in the study group were lower when compared with the control group; the levels of serum interleukin-8(IL-8), white interleukin-17(IL-17), interleukin -6(IL-6), transforming growth factor beta 1 (TGF-beta 1), serum gastrin in 17(G17), pepsinogen Ⅰ(PG Ⅰ) adn pepsinogen Ⅱ (PG Ⅱ) of the study group were lower when compared with the control, the difference was statistical significant (P<0.05); The main adverse reactions during the treatment were nausea, vomiting, dizziness, diarrhea, the incidence of adverse reactions in the study was 4.49%, which was significantly less than the control group (13.48%), the difference was statistical significant. Conclusion Bifidobacterium triple viable powder combined with triple therapy is effective in the treatment of chronic gastritis with Hp infection. It can effectively reduce the clinical symptoms, reduce serum cytokines levels, and inhibit gastrin 17 and pepsin release, with high safety.